江苏吉贝尔药业股份有限公司第四届董事会第十六次会议决议公告

Group 1 - The company held its fourth board meeting on April 23, 2025, to discuss and approve adjustments to the 2025 restricted stock incentive plan [2][3] - The number of initial grant recipients was adjusted from 559 to 542, and the total number of restricted shares granted was reduced from 6.4878 million to 6.4698 million [3][27] - The total number of restricted shares planned for the incentive program was adjusted from 8.0878 million to 8.0698 million, with 1.6 million shares reserved for future grants [3][27] Group 2 - The board approved the initial grant of restricted shares at a price of 12.14 yuan per share, with the grant date set for April 23, 2025 [8][34] - The total number of restricted shares granted was 6.4698 million, representing 3.25% of the company's total share capital at the time of the grant [34][35] - The incentive plan is designed to enhance employee motivation and retention, particularly among key personnel [29][53] Group 3 - The adjustments made to the incentive plan were within the authorization granted by the company's first extraordinary general meeting of 2025, thus not requiring further shareholder approval [7][16] - The monitoring committee confirmed that the adjustments complied with relevant laws and regulations, ensuring that the recipients of the restricted shares met all eligibility criteria [12][30] - The company conducted a self-examination regarding insider trading prior to the announcement of the incentive plan and found no violations [25][38]